My bush man science understanding is that the 2RT is effective for a sub-set of patients with intermediate AMD (i.e. those who did not have coexistent reticular pseudodrusen (RPD)). It would be good to understand how much of the US$10bn market is now available to them and also the size of the VEGF market for patients not having RPD. The investor call tomorrow should be very informative.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.51M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.5¢ | $40.71K | 325.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 119978 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 571105 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| EYE (ASX) Chart |